Mathew Blackman
Stock Analyst at Stifel
(1.44)
# 1656
Out of 5,352 analysts
67
Total ratings
54.84%
Success rate
14.14%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
INGN Inogen | Maintains: Hold | 10 7 | 6.37 | 9.89% | 12 | May 8, 2025 | |
TNDM Tandem Diabetes Care | Maintains: Buy | 60 31 | 20.97 | 47.83% | 6 | May 1, 2025 | |
PEN Penumbra | Maintains: Strong Buy | 301 318 | 255.89 | 24.27% | 2 | Apr 24, 2025 | |
CLPT ClearPoint Neuro | Maintains: Strong Buy | 19 25 | 12.75 | 96.08% | 3 | Apr 1, 2025 | |
BBNX Beta Bionics | Initiates Coverage On: Buy | 25 | 18.35 | 36.24% | 1 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Hold | 245 293 | 320.06 | -8.45% | 3 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 92 94 | 59.35 | 58.38% | 5 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 18 24 | 11.01 | 117.98% | 5 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 6 3 | 1.33 | 125.56% | 1 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Hold | 50 | n/a | n/a | 1 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 90 100 | 86.69 | 15.35% | 11 | Aug 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 19 16 | 12.54 | 27.59% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 18 11 | 8.84 | 24.43% | 4 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 10 | n/a | n/a | 3 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 18 16 | n/a | n/a | 2 | Mar 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 64 | n/a | n/a | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 30 | n/a | n/a | 2 | Aug 26, 2020 |